Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 12 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [ENERGITO® 2]
Conditions
Interventions
Tiotropium
Olodaterol
+2 more
Locations
45
United States
Jasper Summit Research, LLC
Jasper, Alabama, United States
Clinical Trial Connection
Flagstaff, Arizona, United States
California Research Medical Group, Inc.
Fullerton, California, United States
Allergy and Asthma Specialists Medical Group
Huntington Beach, California, United States
California Medical Research Associates Inc.
Northridge, California, United States
IMMUNOe Research Centers
Centennial, Colorado, United States
Start Date
August 14, 2017
Primary Completion Date
April 8, 2019
Completion Date
May 6, 2019
Last Updated
April 16, 2020
NCT06712563
NCT07518472
NCT06831994
NCT02755974
NCT07363980
NCT03044847
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions